Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC)

被引：0
|
作者：
Hamilton, Erika P.
Jauhari, Shekeab
Moore, Kathleen N.
Rini, Brian I.
McLeod, Robert
Lin, Jie
Izumi, Nanae
Kundu, Madan Gopal
Myobatake, Yusuke
Laadem, Abderrahmane
Noguchi, Yutaka
Kirui, Julius
Spigel, David R.
机构：
[1] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[2] Sarah Cannon Res Inst, Florida Canc Specialists, Lake Mary, FL USA
[3] Univ Oklahoma, HSC, Sarah Cannon Res Inst, Stephenson Canc Ctr, Oklahoma City, OK USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[5] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[6] Daiichi Sankyo, Basking Ridge, NJ USA
[7] Daiichi Sankyo Co Ltd, Tokyo, Japan
[8] Sarah Cannon Dev Innovat, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3002
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
    Rodon, Jordi
    Tawbi, Hussein A.
    Thomas, Anne L.
    Stoller, Ronald G.
    Turtschi, Christian P.
    Baselga, Jose
    Sarantopoulos, John
    Mahalingam, Devalingam
    Shou, Yaping
    Moles, Melissa A.
    Yang, Lin
    Granvil, Camille
    Hurh, Eunju
    Rose, Kristine L.
    Amakye, Dereck D.
    Dummer, Reinhard
    Mita, Alain C.
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909
  • [32] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Park, John J.
    Gao, Bo
    Beecroft, Claire
    Wilkinson, Kate Jessica
    Parsonson, Andrew
    Zhang, Karl
    Yan, Xiangyun
    Wang, Ni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] First-in-human (FIH) phase I dose escalation study (part A) of the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in uveal melanoma (part B).
    Di Giacomo, Anna Maria
    Santangelo, Federica
    Amato, Giovanni
    Simonetti, Elena
    Graham, Jill
    Lahn, Michael M. F.
    Di Conza, Giusy
    Hammett, Tracey
    Zorrilla, Rebeca
    Durini, Marco
    Tan, Ziyang
    Tadepally, Lakshmikanth
    Brodin, Petter
    Occhipinti, Mariaelena
    Simonelli, Matteo
    Carlo-Stella, Carmelo
    Santoro, Armando
    Spiliopoulou, Pavlina
    Evans, T. R. Jeffry
    Maio, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
    Brugarolas, James
    Obara, Gregory
    Beckermann, Kathryn E.
    Rini, Brian
    Lam, Elaine T.
    Hamilton, James
    Schluep, Thomas
    Yi, Min
    Wong, So
    Mao, Zhongping Lily
    Gamelin, Erick
    Tannir, Nizar M.
    CLINICAL CANCER RESEARCH, 2024, 30 (11) : 2402 - 2411
  • [35] Safety, tolerability, pharmacokinetics, and antitumor activity of FDA022-BB05 in patients with advanced/ metastatic solid tumors: A multicenter, open-label, first-in-human, phase I/Ib study
    Wang, X.
    Li, Y.
    Sun, J.
    Sun, Y.
    Li, H.
    Li, H.
    Wang, J.
    Ling, X.
    Yang, J.
    Yan, Y.
    Wang, X.
    Sun, W.
    Liu, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1420 - S1421
  • [36] Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.
    Zhou, Fei
    Li, Wei
    Chen, Yu
    Lin, Jing
    Chen, Ling
    Zhang, Huishan
    Dong, Xiaorong
    Tong, Fan
    Zhang, Ruiguang
    Yin, Yongmei
    Liang, Yan
    Yang, Nong
    Hu, Sheng
    Zhuang, Wei
    Li, Tao
    Cai, Shengli
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors
    Jimeno, Antonio
    Gordon, Michael
    Chugh, Rashmi
    Messersmith, Wells
    Mendelson, David
    Dupont, Jakob
    Stagg, Robert
    Kapoun, Ann M.
    Xu, Lu
    Uttamsingh, Shailaja
    Brachmann, Rainer K.
    Smith, David C.
    CLINICAL CANCER RESEARCH, 2017, 23 (24) : 7490 - 7497
  • [38] Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients
    Von Hoff, Daniel D.
    Rudin, Charles M.
    LoRusso, Patricia M.
    Borad, Mitesh J.
    Korn, Ronald L.
    Heath, Elisabeth I.
    Yauch, Robert
    Darbonne, Walter C.
    Kadel, Edward E., III
    Zerivitz, Kenn L.
    Nelson, Lisa E.
    Mackey, Howard
    Marsters, James C., Jr.
    de Sauvage, Frederic J.
    Low, Jennifer A.
    CANCER RESEARCH, 2008, 68 (09)
  • [39] A Phase I first-in-human (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870).
    Boni, Valentina
    Rixe, Oliver
    Rasco, Drew
    Gomez-Roca, Carlos
    Calvo, Emiliano
    Morris, John C.
    Tolcher, Anthony W.
    Assadourian, Sylvie
    Guillemin, Helene
    Delord, Jean-Pierre
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [40] Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors
    Hidalgo, Manuel
    Le Tourneau, Christophe
    Massard, Christophe
    Boni, Valentina
    Calvo, Emiliano
    Albanell, Joan
    Taus, Alvaro
    Sablin, Marie-Paule
    Varga, Andrea
    Bahleda, Ratislav
    Krieter, Oliver
    Markovtsova, Lada
    Carlile, David
    Lahr, Angelika
    Nayak, Tapan
    Lechner, Katharina
    Koehler, Astrid
    Van Uffelen, Ingrid
    Martinez Garcia, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345